Emma Walmsley

9 results

GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine. Photograph: Loriene Perera/Reuters

GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to f(...)

Photograph: iStock

UK pharmaceutical company GlaxoSmithKline is poised to name Jonathan Symonds, a former executive at rivals AstraZeneca and Novartis, as its next chair(...)

The new joint venture with Pfizer is expected to generate total annual cost savings of £500 million by 2022

GlaxoSmithKline plans to split into two businesses – one for prescription drugs and vaccines, the other for over-the-counter products – after forming (...)

Tesaro brings to GSK a marketed product for ovarian cancer, Zejula, which belongs to a promising new class of medicines.  Photograph: Toby Melville/Reuters

GlaxoSmithKline has agreed to buy US cancer specialist Tesaro for $5.1 billion (€4.5 billion), marking a major biotech investment by chief executive E(...)

Pfizer’s Advil  on a drugstore shelf. GlaxoSmithKline has withdrawn from the race to buy the consumer healthcare business that pfizer estimates to be worth $20 billion. Photograph: Mario Anzuoni/Reuters

GlaxoSmithKline has withdrawn from the race to buy Pfizer’s consumer healthcare business, the British company said on Friday, endangering an auction t(...)

GlaxoSmithKline building in Hounslow, west London: GSK, one of Britain’s two Big Pharma firms, decided to abandon plans for a new manufacturing plant in Ulverston in Cumbria. Photograph: Luke MacGregor GlaxoSmithKline building in Hounslow, west London: GSK, one of Britain’s two Big Pharma firms, decided to abandon plans for a new manufacturing plant in Ulverston in Cumbria. Photograph: Luke MacGregor

In a week when the UK’s Eurosceptic international trade minister Liam Fox suggested the British economy could easily manage without a trade deal with (...)

GlaxoSmithKline: has pledged new products will generate £6 billion in sales next year.

GlaxoSmithKline, the UK’s biggest drugmaker, posted a 31 per cent gain in first-quarter profit, helped by a weaker pound and rising sales of its drugs(...)

Emma Walmsley will be paid an annual base salary of about £1 million

Emma Walmsley, poised to take over as the first female chief executive of GlaxoSmithKline, will earn about a quarter less than her predecessor Andrew (...)

Emma Walmsley: she will join the board on January 1st, and take the helm of the company on March 31st

GlaxoSmithKline promoted Emma Walmsley to be the new chief executive officer of the UK’s largest drugmaker, succeeding Andrew Witty when he retires. (...)